Publikationen Immunologie

Watzl C:

How to trigger a killer: modulation of natural killer cell reactivity on many levels. Adv Immunol 124: 137-170 (2014)

Windheim M, Southcombe JH, Kremmer E, Chaplin L, Urlaub D, Falk CS, Claus M, Mihm J, Braithwaite M, Dennehy K, Renz H, Sester M, Watzl C, Burgert HG:

A unique secreted adenovirus E3 protein binds to the leukocyte common antigen CD45 and modulates leukocyte functions. Proc Natl Acad Sci U S A 110: E4884-E4893 (2013)

Cohnen A, Chiang SC, Stojanovic A, Schmidt H, Claus M, Saftig P, Janßen O, Cerwenka A, Bryceson YT, Watzl C:

Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage. Blood 122: 1411-1418 (2013)

Koch J, Steinle A, Watzl C, Mandelboim O:

Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol 34: 182-191 (2013)

Meinke S, Watzl C:

NK cell cytotoxicity mediated by 2B4 and NTB-A is dependent on SAP acting downstream of receptor phosphorylation. Front Immunol 4: article 3 (2013) (6 pp)

Momburg F, Watzl C, Cerwenka A:

NK cells - versatile tools for viral defense and cancer treatment. Eur J Immunol 43: 860-863 (2013)

Balzarolo M, Watzl C, Medema JP, Wolkers MC:

NAB2 and EGR-1 exert opposite roles in regulating TRAIL expression in human Natural Killer cells. Immunol Lett 151: 61-67 (2013)

Watzl C, Sternberg-Simon M, Urlaub D, Mehr R:

Understanding natural killer cell regulation by mathematical approaches. Front Immunol 3: 359 (6 pp) (2012)

Hartmann J, Tran TV, Kaudeer J, Oberle K, Herrmann J, Quagliano I, Abel T, Cohnen A, Gatterdam V, Jacobs A, Wollscheid B, Tampé R, Watzl C, Diefenbach A, Koch J:

The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding. J Biol Chem 287: 31527-31539 (2012)

Hassold N, Seystahl K, Kempf K, Urlaub D, Zekl M, Einsele H, Watzl C, Wischhusen J, Seggewiss-Bernhardt R:

Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int J Cancer 131: E916-E927 (2012)